Physician profile
Ama Alexis
NPI 1700978681
$119,973.48
in general payments reported to CMS, 2019-2025
32 companies · $49K in 2025
The $49K reported for 2025 was more than what 96% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,004 · 2020: $6,649 · 2021: $2,249 · 2022: $7,283 · 2023: $15K · 2024: $35K · 2025: $49K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $53K · Consulting Fee: $32K · Food and Beverage: $8,672 · Travel and Lodging: $5,537 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $52,617.41 |
| Consulting Fee | $31,853.00 |
| Food and Beverage | $8,671.95 |
| Travel and Lodging | $5,537.31 |
| Education | $108.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $34,549.37 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $25,236.61 | 2019-2025 | Dupixent |
| Pfizer INC. | $14,350.15 | 2019-2025 | |
| Eli Lilly and Company | $9,564.16 | 2022-2025 | Ebglyss |
| Dermavant Sciences, INC. | $7,597.77 | 2023-2024 | Tapinarof, Vtama |
| Incyte Corporation | $6,485.51 | 2022-2025 | Opzelura, Opzelura |
| Lilly USA, LLC | $5,832.98 | 2021-2025 | Ebglyss |
| Astrazeneca Pharmaceuticals LP | $5,323.57 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Genentech USA, INC. | $4,095.66 | 2019-2025 | Xolair |
| Janssen Global Services, LLC | $1,760.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $1,117.25 | 2019-2025 | |
| Abbvie INC. | $1,043.08 | 2022-2025 | Rinvoq |
| Glaxosmithkline, LLC. | $875.94 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genentech, INC. | $346.32 | 2022-2025 | Xolair |
| Kaleo, INC. | $271.08 | 2020-2024 | Auvi-Q |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $203.66 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $165.72 | 2019-2025 | |
| Optinose US, INC. | $155.69 | 2019-2025 | |
| Leo Pharma INC. | $154.48 | 2022-2025 | Adbry, Anzupgo |
| Aimmune Therapeutics, INC. | $125.04 | 2021 | |
| Alk-Abello, INC | $118.49 | 2019-2023 | Ragwitek, Odactra, Grastek |
| Amgen INC. | $94.42 | 2022-2024 | Tezspire |
| Cmp Pharma, INC. | $93.84 | 2023 | Carospir |
| Greer Laboratories, INC. | $92.40 | 2019 | |
| Organon LLC | $91.56 | 2025 | Vtama |
| Csl Behring | $79.16 | 2019-2023 | Hizentra |
| Shire North American Group INC | $36.18 | 2019 | |
| Pharming Healthcare, INC. | $28.65 | 2023 | Ruconest |
| Teva Pharmaceuticals USA, INC. | $25.15 | 2021 | |
| Hikma Pharmaceuticals USA | $23.96 | 2023 | Ryaltris |
| Grifols USA, LLC | $23.20 | 2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $12.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ama Alexis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.